Study study type PathologyT1T0Patientssample sizesROB Results

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
nivolumab plus ipilimumab
CheckMate 214 (intermediate and poor risk), 2017
  NCT02231749
RCTmetastatic/advanced RCC (mRCC) - 1st line (L1)nivolumab plus ipilimumabsunitinibpatients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component425 / 422some concern
conclusif
  • demonstrated 37 % decrease in deaths (OS) (PE)
  • inconclusive 18 % decrease in progression or deaths (PFS) (PE)
  • suggested 34 % decrease in deaths (OS) (extension)
  • suggested 23 % decrease in PFS (extension)
  • more...
CheckMate 214 (favorable risk) EXPLORATORY, 2017
  NCT02231749
RCTmetastatic/advanced RCC (mRCC) - 1st line (L1)nivolumab plus ipilimumabsunitinibpatients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component, with favorable risk (IMDCC)125 / 124some concern
inconclusive
  • statistically significant 1.2-fold increase in progression or deaths (PFS)
CheckMate 214 (all population), 2017
  NCT02231749
RCTmetastatic/advanced RCC (mRCC) - 1st line (L1)nivolumab plus ipilimumabsunitinibpatients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component550 / 546some concern
inconclusive
  • suggested 32 % decrease in deaths (OS)
  • suggested 29 % decrease in deaths (OS) (extension)
  • suggested 15 % decrease in PFS (extension)